Phospho‐ibuprofen (MDC‐917) incorporated in nanocarriers: anti‐cancer activity <i>in vitro</i> and <i>in vivo</i>

Abstract

Liposome encapsulation of P-I partially protected P-I from esterase-mediated hydrolysis in mice, enhanced the cytotoxicity and bioavailability of P-I and increased its efficacy at inhibiting the growth of human colon cancer xenografts. These results indicate that liposomes are suitable nanocarriers for the delivery of P-I, and that the anti-tumour potential of liposomal P-I merits further evaluation.